Home » Archive

Articles tagged with: Emtriva

Headline, News »

[ by | Nov 16, 2011 10:48 am | Comments Off ]
Gilead And Tibotec To Develop Single-Pill Protease Inhibitor-Based Combination Regimen

Gilead Sciences and Tibotec Pharmaceuticals have finalized an agreement to develop a new once-daily antiretroviral pill that combines the protease inhibitor Prezista with Emtriva, the investigational booster cobicistat, and an investigational new form of Viread called GS 7340.

GS 7340 is expected to be safer and more effective than the current version of Viread (tenofovir). Gilead has stated that GS 7340 will enter Phase 2 clinical trials early next year.

“This is the first time we are developing a protease inhibitor-containing single-tablet regimen, and we’re able to do that based …

Read the full story »

News »

[ by | Jul 18, 2011 12:13 pm | Comments Off ]

Abbott Laboratories To Develop New Combination Antiretroviral Pill – Abbott Laboratories announced last week that it will be developing a new combination antiretroviral pill consisting of Kaletra (lopinavir/ritonavir) and GlaxoSmithKline’s Epivir (lamivudine). According to Abbott, the proposed combination would reduce the number of pills patients have to take and would be more cost-effective than purchasing the medications separately. The combination pill would still need to be taken with at least one other antiretroviral. Abbott is also working on a powder (rather than liquid) formulation of Norvir (ritonavir), which could be added to food or drinks and may be easier for children to take. For more information, please see the Abbott Laboratories press release.

Gilead Sciences Agrees To License New HIV Drugs To Generic Drug Companies In Developing Countries – Gilead Sciences has signed agreements with several generic drug companies in India that will allow them to produce low-cost versions of the antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine) for developing countries. The agreements will extend to the investigational drugs elvitegravir, cobicistat, and the combination “Quad” pill (cobicistat/elvitegravir/emtricitabine/tenofovir) if the drugs are approved. The agreement makes Gilead the first company to join the Medicines Patent Pool, an effort to bring newer antiretrovirals that are still under patent protection to people in developing nations. However, the agreement has faced criticism from Médecins Sans Frontières (also known as Doctors Without Borders) for excluding certain middle-income countries, such as Thailand and Brazil. For more information, please see the press releases from Gilead Sciences and Médecins Sans Frontières.

AIDSinfo Updates “HIV And Its Treatment” Factsheets – AIDSinfo, a website run by the Department of Health and Human Services (DHHS), has updated its factsheets on “HIV and Its Treatment” to include information from the latest DHHS treatment guidelines for adults and adolescents. The factsheets are intended for people with HIV and their friends or families and include information on current treatment recommendations, HIV testing, transmission prevention, and other topics. For more information, please see the updated factsheets (pdf) or the AIDSinfo website.

Featured, Headline, News »

[ by | Jun 28, 2011 1:57 pm | Comments Off ]
Tibotec, Gilead Announce Development Of New Combination Antiretroviral Pill

Tibotec Pharmaceuticals and Gilead Sciences have agreed to develop a new once-daily combination antiretroviral pill that combines the protease inhibitor Prezista with the investigational booster cobicistat.

In addition, the companies are currently in negotiations to develop a second pill combining Prezista, cobicistat, Emtriva, and an investigational new form of Viread called GS 7340.

“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take,” said Dr. Johan Van Hoof, …

Read the full story »

News »

[ by | Jun 13, 2011 2:33 pm | Comments Off ]

Gilead Sciences Receives Subpoena On Manufacturing, Quality, And Distribution Of HIV Drugs – Gilead Sciences has received a subpoena from the U.S. Department of Justice requesting information on its manufacturing, quality, and distribution practices for several drugs, including Atripla (efavirenz/emtricitabine/tenofovir), Emtriva (emtricitabine), Truvada (emtricitabine/tenofovir), Viread (tenofovir), and the proposed combination pill of Truvada plus Edurant (rilpivirine). Gilead has not disclosed the reason for the subpoena but says it will cooperate in the related civil and criminal investigations. For more information, please see the Gilead Sciences press release.

Spring Issue Of ‘Mental Health AIDS’ Is Now Available – The federal government’s Substance Abuse and Mental Health Services Administration (SAMHSA) has released the spring issue of its quarterly newsletter ‘Mental Health AIDS.’ The newsletter covers psychological and mental-health related issues in people with HIV. This issue focuses primarily on prevention, but also discusses topics such as the approval of Egrifta (tesamorelin), factors affecting medication adherence, and stress management. For more information, please see the Mental Health AIDS Newsletter Spring 2011 (pdf).

AIDS Play ‘The Normal Heart’ Wins Three Tony Awards – Larry Kramer’s play ‘The Normal Heart,’ about HIV/AIDS activists in New York City in the early 1980s, has won the Tony award for Best Revival of a Play. Additionally, cast members John Benjamin Hickey and Ellen Barkin won Tony awards for Best Featured Actor and Best Featured Actress, respectively, in a Play. The play opened on Broadway in April and will continue through July 10. For more information, please see the Tony Awards website or The Normal Heart website.

Headline, News »

[ by | Sep 9, 2010 4:34 pm | One Comment ]
HHS Releases Updated Guidelines For Treatment Of HIV-Positive Children And Teens

The United States Department of Health and Human Services has released an updated version of its “Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.”

The guidelines contain updated recommendations in several areas, including diagnosis of HIV in infants, start of antiretroviral therapy, selection of antiretrovirals, and adherence to antiretroviral therapy in children and teenagers.

The guidelines now also include a rating system to indicate the strength of each recommendation, and formatting changes have been implemented to improve readability. For example, a section on drug side effects in …

Read the full story »